European Multi-Centre Post-Market Registry on Thoracic Endovascular Arch Repair Using Castor™ and Cratos™ (CEDAR)

European Multi-Centre Castor™ and Cratos™ Branched Endovascular Arch Repair Registry

The Castor™ and Cratos™ Branched Aortic Stent Graft Systems are medical devices designed for the minimally invasive endovascular treatment of thoracic aortic pathologies in the descending aorta. The goal of this multi-centre retrospective and prospective observational registry study is to capture the short-, medium- to long-term safety and performance data of how Castor™ and Cratos™ stent-grafts work in real-world settings (everyday medical practice). The aim is to study approximately 100 patients in European hospitals, with competitive enrollment.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Detailed Description

The CEDAR registry is a post-market clinical study with retrospective and prospective enrollment and retrospective and prospective data collection.

Study Type

Observational

Enrollment (Estimated)

100

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

      • Hamburg, Germany, 20099
        • Recruiting
        • ASKLEPIOS Kliniken St. Georg
        • Contact:
        • Principal Investigator:
          • Thomas A Koeppel, Prof. Dr. med.
        • Sub-Investigator:
          • Hans Christian Voigt, Dr. med. univ.
      • Münster, Germany, 48149
        • Recruiting
        • Universitätsklinikum Münster (UKM)
        • Contact:
        • Principal Investigator:
          • Alexander Oberhuber, Dr. med. univ.
      • Sion, Switzerland, 1951
        • Recruiting
        • Hopital de Sion
        • Contact:
        • Principal Investigator:
          • Daniel Danzer
      • Zurich, Switzerland, CH-8091
        • Recruiting
        • Universitätsspital Zürich (USZ)
        • Contact:
        • Principal Investigator:
          • Alexander Zimmermann, Prof. Dr. med.
        • Sub-Investigator:
          • Benedikt Reutersberg,, PD Dr. med.

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

approximately 100 patients in Europe, competitive enrolment

Description

Inclusion Criteria:

  • Implantation of a Castor™ or Cratos™ single branch endoprothesis with incorporation of the left subclavian artery
  • Age >18 years

Exclusion Criteria:

  • Patients allergic to the materials of the device;
  • Patients with severe or potentially systemic infections that increase the chance of graft infection;
  • Minors and pregnant women;
  • Branch for other supra-aortic vessels than the LSA
  • Rejection of participation.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Cohort 1: patients treated with Castor™
Arch involving aortic pathologies treated with the Castor™ stent graft system.
Treatment of subjects diagnosed with thoracic aortic pathologies using the Castor™ Branched Aortic Stent-Graft and Delivery System. Follow up as per institutional standard of care.
Cohort 2: patients treated with Cratos™
Arch involving aortic pathologies treated with the Cratos™ stent graft system.
Treatment of subjects diagnosed with thoracic aortic pathologies using the Cratos™ Branched Aortic Stent-Graft and Delivery System. Follow up as per institutional standard of care.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
30-day all-cause mortality
Time Frame: 30 days
A measure of the total number of patients participating in the CEDAR study who die from any cause within 30 days of the implantation of the branched aortic stent graft - Castor™ or Cratos™.
30 days
Technical success rate
Time Frame: 24 hours
Technical Success is defined as successful access and deployment of the endograft, including implantation of the branch into the target vessel, with patency of the branch and no evidence of type I or type III endoleak on completion angiography or cone-beam computed tomography. Additional intra-operative measures to achieve this, such as ballooning or branch extension with additional stent grafts, are also considered as primary technical success.
24 hours

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Clinical success rate at 30 days, 6 months and at 1 - 5 years
Time Frame: at 30 days, 6 months and at 1 - 5 years
This is defined as Technical Success plus the absence of aortic related death, aortic rupture, graft infection, sac expansion > 5mm, graft migration >10mm, persistent endoleaks type I and III requiring re-intervention, conversion to open surgery, permanent paraplegia, disabling stroke or permanent dialysis.
at 30 days, 6 months and at 1 - 5 years
Rate of Endoleak
Time Frame: at 30 days, 6 months, and at 1 - 5 years
at 30 days, 6 months, and at 1 - 5 years
Branch occlusion rate
Time Frame: at 30 days, 6 months, and 1-5 year
at 30 days, 6 months, and 1-5 year
Rate of perioperative retrograde type A aortic dissections
Time Frame: 30 days, 6 months, and at 1 - 5 years
30 days, 6 months, and at 1 - 5 years
Rate of reintervention
Time Frame: at 30 days, 6 months, and at 1-5 years
at 30 days, 6 months, and at 1-5 years
Combined endpoint major adverse events
Time Frame: at 30-days, 6 months and 1 year
all-cause mortality, myocardial infarction, respiratory failure with postoperative prolonged mechanical ventilation > 24h, renal function declining in a GFR > 50% reduction to perioperative, bowel ischemia requiring surgical resection, major stroke and permanent paraplegia.
at 30-days, 6 months and 1 year
Incidence rate of spinal cord ischemia for the duration of the study
Time Frame: at 30 days, 6 months, and at 1 - 5 years
at 30 days, 6 months, and at 1 - 5 years
Stroke rate
Time Frame: at 30 days, 6 months, and at 1 - 5 years
at 30 days, 6 months, and at 1 - 5 years
All-cause mortality
Time Frame: at 30 days, 6 months, and at 1 - 5 years
at 30 days, 6 months, and at 1 - 5 years

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Investigators

  • Study Director: Jing Wang, Shanghai MicroPort Endovascular MedTech(Group)Co., Ltd

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

September 12, 2025

Primary Completion (Estimated)

October 1, 2028

Study Completion (Estimated)

December 1, 2033

Study Registration Dates

First Submitted

May 20, 2026

First Submitted That Met QC Criteria

June 23, 2026

First Posted (Actual)

June 25, 2026

Study Record Updates

Last Update Posted (Actual)

June 25, 2026

Last Update Submitted That Met QC Criteria

June 23, 2026

Last Verified

June 1, 2026

More Information

Terms related to this study

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.